Navigation Links
Less Is More With Acute Myeloid Leukemia Drug
Date:3/16/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, March 16 (HealthDay News) -- A lower dose of the drug cytarabine work as well as the high doses that are typically used to treat acute myeloid leukemia, and with fewer side effects, a new Dutch study finds.

Cytarabine is used in the treatment of acute myeloid leukemia (AML), along with other chemotherapy drugs and stem cell transplantation. Cytarabine resembles a normal cell nutrient needed by cancer cells to grow. However, when these cells take up cytarabine, the drug actually interferes with their growth.

"The high-dose cytarabine schedules represent an unnecessary overdose causing excess toxicity with no apparent clinical benefit," said lead researcher Dr. Bob Lowenberg, a professor of hematology at Erasmus University Medical Center in Rotterdam. "The lower dose level is sufficient."

The report is published in the March 17 issue of the New England Journal of Medicine.

For the study, Lowenberg's team compared two different intravenous doses of cytarabine in patients with AML. One group of 431 patients was given a lower dose of the drug, while 429 were given a high dose, which is the current standard dose.

Patients who had a complete response to the drug after the first two cycles were taken off the drug, and treatment continued with another type of chemotherapy or a stem cell implant.

Over five years of follow-up, the researchers found no difference between the two groups in terms of remission. Eighty percent of those who received the lower dose had a complete remission, as did 82 percent of those who were given the higher dose.

There was also no significant difference in probability of relapse (34 percent of those given the lower dose and 35 percent of those who received the higher dose), or in overall survival (40 percent in the lower-dose group and 42 percent in the high-dose group).

Not only that, but patients receiving the high doses were more likely to suffer side effects than those given the lower doses, the researchers added. These included skin reactions and gastrointestinal and ocular toxic effects. Also, those given the high dose had longer hospital stays and delays in the recovery of white blood cells and platelets.

"The current standard of treatment with high-dose cytarabine, one of the major chemotherapeutic agents applied in the treatment of acute myeloid leukemia, represents an overdose," Lowenberg said.

One-tenth of the standard dose produces equally effective treatment, but with less toxicity, shorter hospital stays and fewer transfusions, he added.

"The lower-dose level also involves reduced costs," Lowenberg said. "These results set a new standard of care for the therapy of acute myeloid leukemia."

Dr. Mark H. Kirschbaum, an associate member for malignant hematology at the Nevada Cancer Institute in Las Vegas, said that "this is a very important study that will likely impact upon the treatment of patients with acute myeloid leukemia, particularly the older patient population, who clinically have always seemed to suffer from significant toxicity with higher-dose regimens."

"Hopefully progress in the molecular therapeutics of leukemia will allow us to more safely treat patients, particularly the older patients who make up the large majority of new AML patients, in a less toxic manner," he said.

More information

For more information on acute myeloid leukemia, visit the Leukemia & Lymphoma Society.

SOURCES: Bob Lowenberg, M.D., Ph.D., professor, hematology, Erasmus University Medical Center, Rotterdam, the Netherlands; Mark H. Kirschbaum, M.D., associate member, malignant hematology, Nevada Cancer Institute, Las Vegas; March 17, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Potential new treatment to reduce the burden of atherosclerosis in acute coronary syndrome patients
2. No Benefit to Lowering Blood Pressure in Acute Stroke: Study
3. Most X-Rays, Scans Unnecessary for Acute Low Back Pain
4. Researchers discover signaling pathway crucial to acute lung injury
5. Gene Activity May Affect Acute Myeloid Leukemia Outcome
6. Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children
7. Acute Cardiac Care 2010
8. Brain responds same to acute and chronic sleep loss
9. Diabetes patients admitted for acute exacerbations of COPD have longer hospital stay
10. Talyst Reaches Major Milestone: 500 Implementations in Long-Term Care, Acute Care and Corrections
11. Study finds rotavirus vaccine greatly reduces hospitalizations for acute gastroenteritis in children
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Less Is More With Acute Myeloid Leukemia Drug 
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology: